

985.498

# PATENT SPECIFICATION

DRAWINGS ATTACHED

985.498



Date of Application and filing Complete Specification: April 19, 1962.

No. 15352/62.

Application made in Denmark (No. 1691) on April 25, 1961.

Complete Specification Published: March 10, 1965.

© Crown Copyright 1965.

Index at acceptance:—C3 H3; A5 B(2G, 2S, 2Z, 12A)

Int. Cl.:—A 61 k, C 07 g

The inventor of this invention in the sense of being the actual adviser thereof within the meaning of Section 16 of the Patents Act 1949 is VILLY JOHANNES JENSEN, 383 B, Tårnvej, Copenhagen/Vanløse, Denmark, a Danish subject.

## COMPLETE SPECIFICATION

### Improvements in or relating to Plasmin Preparations

We, NOVO TERAPEUTISK LABORATORIUM A/S, a Danish Company of 115, Fuglebakkevej, Copenhagen, Denmark, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

It is known to use sterile plasmin solutions for different therapeutic purposes in which it is endeavoured to utilize the proteolytic properties of the plasmin. The mode of administration depends on the character of the malady which it is intended to relieve or to cure. Thus, use has been made of injections e.g. in case of empyema, hemothorax and sinusitis, and infusions, e.g. in case of thromboses and edemata. Further use has been made of instillations, e.g. in connection with fistulae of different kind and vaginitis. Use has also been made of surface application, e.g. in connection with wound treatments.

Usually the activity of plasmin solutions is expressed in the number of plasmin units per milliliter. However, no definition of a plasmin unit has until now been internationally adopted. Here and in the following one plasmin unit means the amount of plasmin causing in 20 minutes the formation of decomposition products being soluble in perchloric acid and having an extinction of 1 unit at 275mu under the following experimental conditions:

1 milliliter of the plasmin solution the activity of which is to be determined and the pH of which is 7.5 is added to two test tubes each containing in 0.4 molar phosphate buffer (pH 7.50) 1 milliliter of a 3 per cent's solution of Hammarsten Casein said solution having been preheated to 35.5°C. After standing for 2 minutes in thermostat at 35.5°C there are added to one of the tubes 3 milliliters of [F ]

a 1.7 molar solution of perchloric acid in distilled water, and after standing for 22 minutes at 35.5°C there is added to the other tube the same quantity of perchloric acid solution. By the addition of the perchloric acid a precipitation takes place, and the two test tubes now stand for 20 minutes whereafter filtration two times through filtering paper (J. H. Munktells unrivalled Genuine Swedish Filtering Paper No. 0.9cm) is carried out. The extinction of the two solutions is thereafter measured at 275 mu in a Beckman D U Spectrophotometer (1 cm quartz cuvette), the value of the sample having stood for 2 minutes being used as blind value. The plasmin solution the activity of which is to be determined is diluted to such an extent that the extinction does not exceed 0.5 as at higher plasmin concentrations no proportionality exists between the extinction and the plasmin concentration.

While an aqueous plasmin solution having a pH-value of 2 to 3 is practically completely stable at temperatures up to 35°C, the same plasmin solution with neutral reaction (pH 7 or the pH of the blood) is unstable provided the solution has not been greatly diluted. Thus, for instance, if one makes it a condition that the highest loss of plasmin permissible in the solution in the course of 2 hours at 25°C is 20 per cent, plasmin solutions containing more than about 0.1 unit per milliliter would normally be considered unstable.

As the plasmin solutions used for therapeutic purposes contain considerably more plasmin, one has hitherto been compelled to use freshly prepared plasmin solutions and to put up with possible losses of plasmin.

The primary object of this invention is to provide an improved plasmin preparation.

The present invention is based on the observation that the stability of therapeutic-

ally useful plasmin preparations can be considerably improved by adding thereto a specific quantity of one or more amino acids. Several investigators have previously carried out scientific tests in respect of the effect caused by an addition of different amino acids to aqueous systems containing plasmin and its porenzyme plasminogen. These qualitative tests have shown that according to their chemical structure the employed amino acids, even in very low concentrations, are able to inhibit the conversion of the plasminogen into plasmin in the living organism to a more or less pronounced degree and thereby to prevent temporarily a plasmin activity *in vivo*. This does not, however, permit to draw any specific conclusions as to the influence of amino acids on the stability and activity of plasmin solutions *in vitro*.

The addition of amino acid has also proved to augment the solubility of the plasmin in the aqueous medium. While a neutral solution of plasmin in water becomes turbid due to a precipitation of plasmin when the plasmin concentration is 0.01 unit and more per milliliter, it is possible by the addition of an amino acid to produce clear neutral plasmin solutions having a plasmin concentration up to 25 units per milliliter.

By the tests having led to the present invention and in which use has been made of a long series of different amino acids it has been found that the chemical structure of the amino acids influences their stabilizing effect. Thus it has proved to be most effective to use aliphatic amino monocarboxylic acids, especially those in which at least one amino group in the amino acid is bound to a carbon atom which is separated from the carboxylic group(s) of the amino acid by at least one carbon atom. Particularly appropriate are aliphatic amino monocarboxylic acids with more than 3 carbon atoms and a terminal amino group since the stabilizing effect obtainable seems to be the better the longer the distance is between the carboxylic group of the amino acid and its amino group(s).

According to one aspect of this invention we provide a plasmin preparation for therapeutic use, comprising plasmin and as stabilizer and solubilizer therefor 0.002 millimole to 1 millimole, preferably 0.05 millimole to 1 millimole of amino acid per unit of plasmin. The plasmin preparation may for instance comprise a solid mixture of plasmin and amino acid, or an acidified aqueous plasmin solution containing amino acid.

According to another aspect of this invention we provide a process for making a plasmin preparation as defined in the preceding paragraph, which comprises dissolving plasmin in an aqueous injectable liquid medium at a pH value of 2 to 3, adding the required amount of amino acid, adjusting the pH value of the resultant mixture to about 7, filtering the mixture under sterile conditions and freeze-drying the mixture.

In order to illustrate the stabilizing effect obtainable according to the present invention, reference is made in the following to a series of stabilizing experiments, i.e. with regard to the accompanying drawing in which:

Figures 1 and 2 show graphically the stabilizing effect of different amino acids.

The stabilizing effect of a long series of amino acids has been examined in connection with plasmin originating from swine blood and dissolved in phosphate buffer (pH 7.5). An aqueous solution of the amino acid in question is mixed with the plasmin solution while diluting, if desired, in such proportions that the produced mixture contains about 0.4 plasmin units per milliliter and 0.25 millimole of amino acid per plasmin unit if the solubility of the amino acids allows the said amino acid concentration. If not, a saturated amino acid solution is employed. The amino acid-containing plasmin solution thus produced is placed in a thermostat at 35.5 C, and at different hours samples are taken which are analysed for plasmin activity reckoned in per cent of the initial activity (about 0.4 unit per milliliter).

TABLE I

Amino acid	% activity after 60 minutes at 35.5° C.	% activity after 120 minutes at 35.5° C.
None	55	43
Glycine	57	44
Guanidino acetic acid	80	68
Creatine	81	60
$\beta$ -alanine	72	66
DL-valine	60	49
DL-leucine	72	53
DL-isoleucine	77	57
DL-norleucine	72	59
L(+)-aspartic acid	60	51
DL-methionine	69	62
$\gamma$ -amino butyric acid	97	87
L(+)-citrulline	64	54
L-arginine	78	65
$\alpha$ -N-acetyl-L-arginine	92	87
L-ornithine	92	81
$\epsilon$ -amino caproic acid	85	80
L-lysine	98	96
<i>m</i> -amino benzoic acid	73	52
<i>o</i> -amino benzoic acid	79	68
<i>p</i> -amino benzoic acid	77	63
DL-phenyl alanine	73	55
L-histidine	64	61
DL-thryptophane	60	48
L(-)-proline	62	54
L(-)-hydroxyproline	69	66
Glycyl glycine	88	77
None	55	43

The curves in Figures 1 and 2 show the stability obtainable under the above mentioned experimental conditions, also after storage at 35.5°C for a longer period of time, while using the mentioned amino acids, the abscissa of the curves indicating the storage period in hours and the ordinate the per cent of the original activity. For comparison the curve of stability of the employed plasmin solution without addition of amino acid is also shown.

It will appear from the experimental material that the stabilizing effect of aliphatic  $\alpha$ -amino acids is not very big at the employed amino acid concentration, the stabilizing effect, however, increasing the longer the carbon chain of the  $\alpha$ -amino acid is. If the carbon chain of the  $\alpha$ -amino acid is branched, the stabilizing effect of the  $\alpha$ -amino acid will also increase. Further, it will be seen that the stabilizing effect of  $\alpha$ -amino acids will increase violently if the amino group is substituted to give the acid a more basic character. Thus, guanidino acetic acid and creatine show a stabilizing effect being considerably better than that of glycine and DL-valine. Moreover, it will be seen that an introduction of acid groups in an  $\alpha$ -amino acid causes the stabilizing effect to decrease. Thus, the stabilizing effect of L(-)-aspartic acid is almost identical with that of glycine.

Aliphatic  $\beta$ -amino acids have a greater stabilizing effect than have  $\alpha$ -amino acids, and with increasing distance between the carboxylic group of the amino and its amino group the stabilizing effect will increase. Thus, e.g.  $\gamma$ -amino butyric acids and  $\epsilon$ -amino caproic acid stabilize considerably better than  $\beta$ -alanine.

The stabilizing effect will remain practically unchanged even if an amino group in  $\alpha$ -position is present in addition to the amino group spaced considerably from the carboxylic group, compare the stabilizing effect of  $\epsilon$ -amino

caproic acid and lysine ( $\alpha,\epsilon$ -diamino caproic acid). Also ornithine ( $\alpha,\delta$ -diamino valeric acid) provides an excellent stabilizing effect.

Also with sulphurous amino acids it is possible to obtain a stabilizing effect, vide e.g. DL-methionine.

The fact that an amino group is substituted with a non-basic group does not prevent the occurrence of the stabilizing effect if the amino acid still has a basic group far away from the carboxylic group. Thus  $\alpha$ -N-acetyl-L-arginine provides an excellent stabilizing effect.

While glycine only shows a faintly stabilizing effect in the employed concentration, a strongly stabilizing effect is obtained with glycyl glycine, which is in conformity with what has been mentioned above i.e. that it is important for the stabilizing effect that an amino group is present so far as possible from the carboxylic group of the amino acid.

The aromatic amino acids tested show a limited stabilizing effect in the employed concentrations. Something similar applies to the tested heterocyclic amino acids L(-)-proline and L(-)-hydroxy proline.

Glycyl glycine is to be considered a dipeptide. Also other dipeptides, e.g. leucyl glycine, alanyl alanine and glycyl valine and higher peptides, may be used though usually the ordinary amino acids are preferred due to the fact that they are more easily available and obtainable at a lower price. For the purposes of the present invention, however, dipeptides are included within the general term "amino acids".

Tests corresponding to the above mentioned ones in which use has been made of plasmin originating from swine blood, have also been carried out under the employment of plasmin originating from oxblood. In the table below the results obtained under the employment of the mentioned amino acids have been compiled.

TABLE II

Amino acid 0.25 millimole per plasmin unit	% activity after 60 minutes at 35.5° C.	% activity after 120 minutes at 35.5° C.
L-lysine	85	83
L-arginine	86	85
$\epsilon$ -amino caproic acid	100	99
None	60	45

It will appear from the table below that amino acids also have a stabilizing effect on solutions of plasmin originating from human

blood. The experimental circumstances are identical to those mentioned above.

TABLE III

Amino acid 0.25 millimole per plasmin unit	% activity after 60 minutes at 35.5° C.	% activity after 120 minutes at 35.5° C.
L-lysine	87	78
$\epsilon$ -amino caproic acid	94	96
None	55	32

As it will appear from table I the stabilizing effect of glycine at a storage temperature of the plasmin solution of 35.5° C is rather insignificant when the glycine is used in an amount of 0.25 millimole per plasmin unit. It is, however, a general rule that an increase of the amino acid concentration within certain limits will cause an increased stability of the plasmin solutions. Thus, if use is made of an addition of glycine in a concentration of 2.5 millimole per plasmin unit, the plasmin solution will after storage at 35.5°C for 60 minutes show 73 per cent of its original activity compared with 57 per cent, only, of the original activity when the glycine has been added in a concentration of 0.25 millimole per plasmin unit. Something similar applies to the other amino acids which according to table I show a relatively insignificant stabilizing effect at the employed concentration.

If a relatively large amount of the amino acids as e.g. L-lysine or  $\epsilon$ -amino caproic acids showing a strongly stabilizing effect is added to the plasmin solutions, and the solutions are analysed for plasmin activity immediately after the addition, a plasmin activity smaller than

that expected will be found. This is probably due to the fact that the relatively high amino acid concentration will cause formation in appreciable amounts of a plasmin amino acid complex which is not active. If, however, the solutions are diluted before the analysis, the total plasmin activity will be found again. By way of illustration reference may be made to the following experiments:

a) a plasmin solution from swine blood and containing about 0.4 plasmin units per milliliter and 2 millimoles of L-lysine per plasmin unit is produced in phosphate buffer (pH 7.5) whereafter the plasmin activity of the mixture is determined and compared with the activity of the plasmin solution without the amino acid addition and the activity of the mixture is expressed in per cent of the activity of the unmixed plasmin solution. Thereafter a dilution of the solution is carried out expressed in the original volume of the plasmin solution divided by the volume of the plasmin solution after the dilution, and the activity of the diluted solutions is determined. The results of these experiments are compiled in the table below.

TABLE IV

Dilution	Millimole L-lysine per ml	Activity expressed in per cent of the total activity
Undiluted	0.8	88
4:5	0.64	84
3:5	0.48	92
2:5	0.32	100
1:5	0.16	97

b) the same experiment as mentioned sub a) is carried out except that use is made of

$\epsilon$ -amino caproic acid instead of L-lysine. The results are compiled in the table below.

TABLE V

Dilution	Millimole $\epsilon$ -amino caproic acid per ml	Activity expressed in per cent of the total activity
Undiluted	0.8	57
4:5	0.64	65
3:5	0.48	71
2:5	0.32	84
1:5	0.16	93

- As to the amount of amino acid which should be used in obtaining a stabilization utilizable in practice, it should first be mentioned that the stability both of a plasmin solution with no amino addition as well as of a plasmin solution with an addition of amino acid is highly dependent on the temperature at which the solution is stored. At 25°C the half-life period of an unstabilized plasmin solution is about 4 to 5 times bigger than at 35.5°C, provided use has been made of the same plasmin concentration. Also the stability of a plasmin solution which has been stabilized by an amino acid addition is very dependent on the temperature. In order to illustrate this reference may be made to the tables below which, just like table I, show the activity of a plasmin solution containing 0.4 and 0.3 plasmin units per ml, respectively, having varying amounts of L-lysine added thereto and having been stored for 60 minutes and 120 minutes, respectively, at 35.5°C and 25°C, respectively.

TABLE VI

Millimole L-lysine per plasmin unit	% activity after 60 minutes at 35.5° C.	% activity after 120 minutes at 35.5° C.
0.000	55	43
0.031	74	52
0.062	89	73
0.125	99	84
0.25	100	92

TABLE VII

Millimole L-lysine per plasmin unit	% activity after 60 minutes at 25° C.	% activity after 120 minutes at 25° C.
0.00	77	70
0.005	88	78
0.010	91	84
0.021	99	91
0.042	100	99

If only a plasmin loss of about 20 per cent by standing for 2 hours at 25°C and 35.5°C, respectively, is to be allowed, it will be sufficient at the first mentioned temperature to have a lysine concentration of about 0.005 millimole per plasmin unit, while at 35.5°C a lysine concentration of about 0.1 millimole per plasmin unit will be necessary.

Thus it will be seen that the lower limit for the amino acid concentration utilizable in practice does not only depend on the kind of amino acid to be used, but also on the demands which in each individual case will be made on the part of the clinics so far as the stability of the employed plasmin solutions is concerned.

With lysine as an example it will be seen that in order to avoid a plasmin loss by standing for two hours 35.5°C and a plasmin concentration of 0.4 mole per ml it will be necessary to employ a lysine concentration of above 0.25 millimole per plasmin unit while the corresponding lysine concentration at 25°C is 0.04 millimole per plasmin unit. In practice it will, however, not be necessary to make such heavy demands on the stability. It will be possible to tolerate an activity loss of 20 per cent during 2 hours at 25°C.

As to lysine, the lower limit of the amount of lysine necessary in practice is fixed at 0.002 millimole per plasmin unit, and as lysine must be considered one of the amino acids having the most vigorous stabilizing effect use must always be made of at least 0.002 millimole of amino acid per plasmin unit in order to obtain a useful stabilizing effect. It is preferred that the amount of amino acid exceeds 0.005 millimole per plasmin unit. Excellent stabilising effects will be obtained when the amino acid is present in amounts within the range 0.05 millimole to 1 millimole per plasmin unit.

As it will appear from table IV, lysine will, when use is made of a plasmin concentration corresponding to  $\frac{1}{2}$  unit per millimole lysine, have an inactivating effect on the plasmin solution provided the lysine is present in a concentration above 0.32 millimole per ml. As, however, the inactivation, as it also appears from table IV, is reversible, since it disappears by dilution, and as the injection of the plasmin solutions, specially by infusion, causes a vigorous dilution of the plasmin solution to take place, and the removal of amino acids from blood and tissue fluids occurs many times more quickly than the removal of plasmin, it is for the purpose of the invention possible to use lysine in concentrations greatly exceeding 2 millimole per plasmin unit. Actually, there exists no physiological upper limit for the employed amino acid amount beyond the doses having toxic effect and being of a magnitude quite different from the amino acid amounts necessary for the purpose of the invention.

For clinical reasons one will certainly for

intravenous purposes in general hesitate to make use of a plasmin solution containing such an amount of amino acid that a part thereof is present in suspension in undissolved state in the plasmin solution. From a practical point of view the solubility of the amino acid is consequently to be considered as a guide for the maximal amino acid amount which should be used for intravenous injection, including infusion. The solubility of the different amino acids appears from the literature and is in most cases so big as to allow the stabilization aimed at, without the necessity of employing concentrated amino acid solutions.

If the plasmin solution is intended for infusion, the optimal amino acid concentration is the concentration giving the desired stability at the temperature of infusion (10 to 36°C) in the infusion period (up to 3—4 hours). Numerically it will be appropriate to use an amino acid concentration of 0.005 to 1 millimole per plasmin unit dependent on the employed amino acid.

In the tests referred to above use has been made of plasmin solutions having a plasmin content of 0.3 and 0.4 units, respectively, per milliliter. When using more concentrated solutions, e.g. containing 10 plasmin units per milliliter, an appreciable initial loss of plasmin will occur immediately by the adjustment of the pH-value from 2—3 up to neutral reaction unless amino acids are present in sufficient amounts. Thus, in the course of a few minutes an initial loss of 20 per cent may e.g. arise when an acidified plasmin solution containing 10 plasmin units per milliliter is adjusted to pH 7.5 at 25°C even if lysine is present in the solution in an amount of 0.002 millimole per plasmin unit. Such initial loss can, however, be avoided by increasing the amino acid concentration. With a lysine content of 0.04 millimole per plasmin unit it is possible under the above mentioned experimental conditions to avoid completely an initial loss.

In the production of concentrated plasmin solutions having neutral reaction the said circumstances should be taken into account.

In order to obtain the desired stabilization according to the invention it is possible to proceed in different ways.

Thus, a plasmin solution may be produced which solution is sterile filtered whereafter the plasmin is isolated from the solution e.g. by freeze-drying, salting out or precipitation and is filled into vials if such filling has not already taken place during the isolating step. There may also be produced an aqueous amino solution which is sterile filtered and is filled into vials. Immediately before use of the plasmin, the plasmin from the vial is dissolved in the amino acid solution, thereby producing a sterile and stable plasmin solution ready for use.

It is also possible to produce a sterile filtered aqueous plasmin solution containing one or

more amino acids and to bring the mixture into dry state, e.g. by freeze-drying or precipitation and to fill the dry mixture into vials. Immediately before use of the plasmin the dry mixture is dissolved in sterile water, a buffer solution or the like, whereby a stabilized plasmin preparation will be produced.

Further, it is possible to produce a sterile aqueous plasmin solution which is adjusted to pH 1 to 4. Such acid solution is stable for several months if it is stored at 4–5°C. By mixing such solution before use with a sterile aqueous amino acid solution which has either been buffered with one of the normal acid-base-buffer systems or has a sufficient amino acid content, it is possible to obtain a neutral stable plasmin solution.

Finally, it is possible to produce a sterile aqueous plasmin solution containing the necessary amount of amino acid and having been adjusted to a pH-value of 1–5, preferably 2–3. By mixing such solution with a sterile aqueous solution which has either been buffered with one of the normal acid-base-buffer systems, or which merely contains sufficient base, it is possible to arrive at a neutral and stable plasmin solution.

In order to further illustrate the present invention reference is made to the below examples showing the production of stabilized plasmin solutions, preferably useful for infusion purposes.

#### EXAMPLE 1.

50 ml of an aqueous plasmin solution having a pH-value of 2.5 and containing 10 plasmin units per ml are sterile filtered, freeze-dried and filled into vials. 50 ml of 0.2 molar phosphate buffer containing lysine in a concentration of 0.4 mole per liter are sterile filtered and filled into vials, too. Immediately before the use of the plasmin, the freeze-dried plasmin is dissolved in the lysine solution whereby a sterile stabilized plasmin preparation having pH 7.5 is obtained.

#### EXAMPLE 2.

50 ml of an aqueous plasmin solution having a pH-value of 7.5 and containing 10 plasmin units per ml and 0.1 mole  $\epsilon$ -amino caproic acid per liter are sterile filtered, freeze-dried and filled into vials. Immediately before the use of the plasmin, the freeze-dried preparation is dissolved in 50 ml of sterile distilled water whereby a sterile stabilized plasmin preparation having pH 7.5 is obtained.

#### EXAMPLE 3.

45 ml of an aqueous plasmin solution having a pH-value of 2.5 and containing 20 plasmin units per ml are sterile filtered and filled into vials. 10 ml of 1 molar phosphate buffer (pH 7.5) containing lysine in a concentration of 1 mole per liter, are sterile filtered and filled into vials, too. Immediately before the use of the plasmin solution, 5 ml of the lysine solution are added thereto, whereby a sterile

stabilized plasmin preparation having a pH-value of 7.5 is produced.

#### EXAMPLE 4.

45 ml of an aqueous plasmin solution having a pH-value of 3.0 and containing 6 plasmin units per ml and 948 mg of L-arginine hydrochloride are sterile filtered and filled into vials. 10 ml of 1 molar phosphate buffer are sterile filtered and filled into vials, too. Immediately before the use of the plasmin solution 5 ml of the phosphate buffer are added thereto, whereby a sterile stabilized plasmin preparation with pH 7.0 is arrived at.

#### EXAMPLE 5.

An aqueous solution of plasmin in diluted sulphuric acid having pH 2–3 is sterile filtered and freeze-dried. A solution of L-lysine-monohydrochloride in phosphate buffer is sterile filtered and freeze-dried. The freeze-dried substances are mixed together in such proportions that the mixture contains 0.04 millimole of lysine per plasmin unit. An amount of the produced mixture corresponding to 500 plasmin units is under sterile conditions transferred to an infusion bottle having a volume of 500 ml, and the bottle is sealed after partial evacuation. Immediately before the use an injectable solvent in appropriate amount is added to the bottle, e.g. in the form of sterile distilled water, a sterile glucose solution or sterile sodium chloride solution. The said addition is facilitated due to the partial vacuum in the bottle. The pH-value of the solution will be between 7.0 and 7.5.

#### EXAMPLE 6.

To 1 liter of an aqueous plasmin solution having pH 2.5 and containing 5.0 units of plasmin per milliliter 36.6 g of L-lysine monohydrochloride are added at 0 to 5°C. When the lysine has been dissolved pH is adjusted to 7.5 and still at 0 to 5°C 1.02 g of  $\text{KH}_2\text{PO}_4$  and 7.56 g of  $\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$  are added. After the phosphate buffer is dissolved the solution is sterile filtered.

The sterile filtered solution is filled into infusion bottles and is freeze-dried. 50 ml of plasmin solution per infusion bottle (300 ml) are used. After freeze-drying the bottles are sealed and labelled.

If desired the sterile filtered solution may be freeze-dried as a whole and the produced powder may thereafter be ground and filled into the infusion bottles.

The effect of the stabilized plasmin solutions according to the invention which solutions have been produced from swine blood, have been tested with excellent results both in experiments with animals and in the clinics. The clinical experiments did not show any antigen effect by the use of the plasmin. Due to the stabilization the employed plasmin solutions contain less amounts of plasmin being decomposed by autolysis giving rise to toxic secondary effects.



In the above examples solutions containing from 1 to 18 plasmin units per ml are obtained. There is, however, nothing to prevent from producing more or less concentrated solutions, e.g. down to 0.02 plasmin units and up to 25 plasmin units per ml or more.

# WHAT WE CLAIM IS:—

1. A plasmin preparation for therapeutic use, comprising plasmin and as stabilizer and solubilizer therefor 0.002 millimole to 1 millimole of amino acid per unit of plasmin.

2. Plasmin preparation according to Claim 1, wherein the amount of amino acid present is 0.05 millimole to 1 millimole per unit of plasmin.

3. Plasmin preparation according to Claim 1 or Claim 2, comprising a solid mixture of plasmin and amino acid.

4. Plasmin preparation according to Claim 1 or Claim 2, comprising an ampoule containing plasmin in solid form and an ampoule containing amino acid in solid or dissolved form.

5. Plasmin preparation according to Claim 1 or Claim 2, comprising an ampoule containing an acidified aqueous plasmin solution and an ampoule containing amino acid in solid or dissolved form.

6. Plasmin preparation according to Claim 1 or Claim 2, comprising an acidified aqueous plasmin solution containing amino acid.

7. Plasmin preparation according to Claim 1 or Claim 2, which is in a form ready for intermediate application and comprises a sterile aqueous plasmin solution having a pH value of about 7 and amino acid.

8. Plasmin preparation according to any preceding claim, wherein the amino acid is an aliphatic amino-monocarboxylic acid.

9. Plasmin preparation according to any one of Claims 1 to 7, wherein the amino acid is one having at least one amino group bound to a carbon atom which is separated from the carboxylic acid group or groups by at least one carbon atom.

10. Plasmin preparation according to any preceding claim, wherein the amino acid is an aliphatic amino-mono-carboxylic acid with more than 3 carbon atoms and a terminal amino group.

11. Plasmin preparation according to any preceding claim, wherein the amino acid is  $\epsilon$ -amino caproic acid or an  $\alpha,\epsilon$ -diamino caproic acid.

12. A plasmin preparation for therapeutic use substantially as herein described with reference to the Examples.

13. A process for making a plasmin preparation as claimed in Claim 1, which comprises dissolving plasmin in an aqueous injectable liquid medium at a pH value of 2 to 3, adding the required amount of amino acid, adjusting the pH value of the resultant mixture to about 7, filtering the mixture under sterile conditions and freeze-drying the mixture.

14. Process according to Claim 13, wherein the amino acid is added to the form of an aqueous solution.

15. A process according to Claim 13 for making a plasmin preparation as claimed in Claim 7, wherein the required amount of sterilised water is added to the freeze-dried mixture to provide a solution ready for immediate application.

16. A process according to any one of Claims 13 to 15 substantially as herein described and exemplified.

17. A plasmin preparation whenever obtained by the process claimed in any one of Claims 13 to 16.

FORRESTER, KETLEY & CO.,

Chartered Patent Agents,  
Jessel Chambers, 88—90, Chancery Lane,  
London, W.C.2, and  
Central House, 75, New Street,  
Birmingham, 2,  
Agents for the Applicants.

Leamington Spa: Printed for Her Majesty's Stationery Office, by the Courier Press (Leamington) Ltd.—1965. Published by The Patent Office, 25 Southampton Buildings, London, W.C.2, from which copies may be obtained.

985498

## COMPLETE SPECIFICATION

1 SHEET

This drawing is a reproduction of  
the Original on a reduced scale